$300.76
3.721.25%
At close: -
$300.76
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
United Therapeutics Analyst Ratings and Price Targets | NASDAQ:UTHR | Benzinga
United Therapeutics Corp has a consensus price target of $366.31 based on the ratings of 16 analysts. The high is $600 issued by Oppenheimer on October 31, 2024. The low is $247 issued by Credit Suisse on May 24, 2022. The 3 most-recent analyst ratings were released by Wells Fargo, JP Morgan, and B of A Securities on April 25, 2025, April 21, 2025, and April 21, 2025, respectively. With an average price target of $327.67 between Wells Fargo, JP Morgan, and B of A Securities, there's an implied 8.95% upside for United Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
JP Morgan
B of A Securities
HC Wainwright & Co.
UBS
1calculated from analyst ratings
Analyst Ratings for United Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/25/2025 | Buy Now | 4.4% | Wells Fargo | Tiago Fauth43% | $395 → $314 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/21/2025 | Buy Now | 18.03% | JP Morgan | Jessica Fye64% | $357 → $355 | Maintains | Overweight | Get Alert |
| 04/21/2025 | Buy Now | 4.4% | B of A Securities | Greg Harrison44% | $314 → $314 | Upgrade | Underperform → Neutral | Get Alert |
| 02/27/2025 | Buy Now | 41.31% | HC Wainwright & Co. | Andrew Fein57% | $425 → $425 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 57.93% | UBS | Ashwani Verma42% | $415 → $475 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 0.41% | Goldman Sachs | Chris Shibutani56% | $243 → $302 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 14.38% | Ladenburg Thalmann | Matthew Kaplan66% | $319 → $344 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 99.49% | Oppenheimer | Hartaj Singh47% | $575 → $600 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 33% | Argus Research | Jasper Hellweg70% | $360 → $400 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 41.31% | HC Wainwright & Co. | Andrew Fein57% | $400 → $425 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 33% | TD Cowen | Joseph Thome28% | $350 → $400 | Maintains | Buy | Get Alert |
| 09/23/2024 | Buy Now | 43.64% | Jefferies | Eun Yang34% | $315 → $432 | Maintains | Buy | Get Alert |
| 08/28/2024 | Buy Now | 91.18% | Oppenheimer | Hartaj Singh47% | $400 → $575 | Maintains | Outperform | Get Alert |
| 08/20/2024 | Buy Now | 26.35% | Wells Fargo | Tiago Fauth43% | $350 → $380 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 33% | HC Wainwright & Co. | Andrew Fein57% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | -6.9% | B of A Securities | Greg Harrison44% | $303 → $280 | Maintains | Underperform | Get Alert |
| 07/25/2024 | Buy Now | 33% | HC Wainwright & Co. | Andrew Fein57% | $300 → $400 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 16.37% | TD Cowen | Joseph Thome28% | $270 → $350 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 6.73% | Morgan Stanley | Terence Flynn66% | $310 → $321 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 23.02% | UBS | Ashwani Verma42% | $300 → $370 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 16.37% | Wells Fargo | Tiago Fauth43% | $325 → $350 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -0.25% | JP Morgan | Jessica Fye64% | $280 → $300 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | -20.2% | Goldman Sachs | Chris Shibutani56% | $218 → $240 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | -0.25% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 33% | Oppenheimer | Hartaj Singh47% | $375 → $400 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 8.06% | Wells Fargo | Tiago Fauth43% | $309 → $325 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | 2.41% | Wedbush | Liana Moussatos77% | $308 → $308 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | -0.25% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | Buy Now | -28.51% | Goldman Sachs | Chris Shibutani56% | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 02/05/2024 | Buy Now | 9.72% | Leerink Partners | Roanna Ruiz34% | → $330 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | -2.25% | JP Morgan | Jessica Fung39% | $290 → $294 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 4.4% | Morgan Stanley | Terence Flynn66% | $318 → $314 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 2.41% | Wedbush | Liana Moussatos77% | $307 → $308 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 5.73% | Morgan Stanley | Terence Flynn66% | $316 → $318 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -10.89% | Ladenburg Thalmann | Matthew Kaplan66% | $256 → $268 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 2.07% | Wedbush | Liana Moussatos77% | $305 → $307 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -0.25% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | -14.88% | Ladenburg Thalmann | Matthew Kaplan66% | $285 → $256 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | -6.9% | Argus Research | Jasper Hellweg70% | $300 → $280 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | 3.07% | UBS | Ashwani Verma42% | $330 → $310 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | 5.07% | Morgan Stanley | Terence Flynn66% | $320 → $316 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -6.9% | JP Morgan | Jessica Fung39% | $265 → $280 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 6.4% | Morgan Stanley | Terence Flynn66% | $330 → $320 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -0.25% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | -0.25% | Argus Research | Jasper Hellweg70% | $250 → $300 | Maintains | Buy | Get Alert |
| 12/06/2022 | Buy Now | 9.72% | Morgan Stanley | Terence Flynn66% | $322 → $330 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 6.4% | UBS | Ashwani Verma42% | → $320 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | -23.53% | Goldman Sachs | Chris Shibutani56% | → $230 | Initiates | → Sell | Get Alert |
| 11/03/2022 | Buy Now | -11.89% | JP Morgan | Jessica Fye64% | $240 → $265 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 7.06% | Morgan Stanley | Terence Flynn66% | $288 → $322 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 24.68% | Oppenheimer | Hartaj Singh47% | $325 → $375 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -0.25% | HC Wainwright & Co. | Andrew Fein57% | $255 → $300 | Maintains | Buy | Get Alert |
| 10/11/2022 | Buy Now | -4.24% | Morgan Stanley | Terence Flynn66% | → $288 | Initiates | → Overweight | Get Alert |
| 05/24/2022 | Buy Now | -20.87% | JP Morgan | Jessica Fye64% | $225 → $238 | Maintains | Overweight | Get Alert |
| 05/24/2022 | Buy Now | -18.54% | Jefferies | Eun Yang34% | $223 → $245 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | -12.55% | Wedbush | Liana Moussatos77% | $236 → $263 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -17.87% | Credit Suisse | Tiago Fauth43% | $219 → $247 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -15.21% | HC Wainwright & Co. | Andrew Fein57% | $248 → $255 | Maintains | Buy | Get Alert |
FAQ
What is the target price for United Therapeutics (UTHR) stock?
The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by Wells Fargo on April 25, 2025. The analyst firm set a price target for $314.00 expecting UTHR to rise to within 12 months (a possible 4.40% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by Wells Fargo, and United Therapeutics downgraded their equal-weight rating.
When was the last upgrade for United Therapeutics (UTHR)?
The last upgrade for United Therapeutics Corp happened on April 21, 2025 when B of A Securities raised their price target to $314. B of A Securities previously had an underperform for United Therapeutics Corp.
When was the last downgrade for United Therapeutics (UTHR)?
The last downgrade for United Therapeutics Corp happened on April 25, 2025 when Wells Fargo changed their price target from $395 to $314 for United Therapeutics Corp.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on April 25, 2025 so you should expect the next rating to be made available sometime around April 25, 2026.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a downgraded with a price target of $395.00 to $314.00. The current price United Therapeutics (UTHR) is trading at is $300.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
